Krystal Biotech, Inc.
KRYS
$306.29
-$10.01-3.17%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 25.15% | 33.95% | 54.51% | 116.09% | 247.53% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 25.15% | 33.95% | 54.51% | 116.09% | 247.53% |
| Cost of Revenue | 7.38% | 14.89% | 19.03% | 106.79% | 311.21% |
| Gross Profit | 26.44% | 35.36% | 57.36% | 116.78% | 243.64% |
| SG&A Expenses | 29.08% | 29.21% | 27.59% | 25.08% | 19.73% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.46% | 21.70% | 21.71% | 27.80% | 32.27% |
| Operating Income | 33.65% | 56.16% | 143.58% | 3,672.19% | 342.64% |
| Income Before Tax | 50.21% | 98.70% | 225.68% | 55.70% | 133.44% |
| Income Tax Expenses | -225.99% | -347.88% | -337.75% | 801.97% | 615.57% |
| Earnings from Continuing Operations | 81.53% | 129.74% | 279.80% | 38.50% | 116.86% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 81.53% | 129.74% | 279.80% | 38.50% | 116.86% |
| EBIT | 33.65% | 56.16% | 143.58% | 3,672.19% | 342.64% |
| EBITDA | 32.62% | 54.02% | 134.42% | 1,937.70% | 362.96% |
| EPS Basic | 79.56% | 127.79% | 275.94% | 35.29% | 118.34% |
| Normalized Basic EPS | 25.67% | 41.20% | 94.94% | 440.38% | 625.72% |
| EPS Diluted | 79.63% | 128.75% | 277.27% | 34.98% | 122.84% |
| Normalized Diluted EPS | 26.02% | 41.86% | 95.51% | 439.69% | 604.04% |
| Average Basic Shares Outstanding | 1.18% | 1.23% | 1.45% | 1.85% | 3.35% |
| Average Diluted Shares Outstanding | 0.88% | 0.83% | 1.43% | 2.37% | 4.96% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |